申请人:Kusumi Kensuke
公开号:US20090192182A1
公开(公告)日:2009-07-30
A compound represented by general formula (I):
a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
化合物的普通公式(I)所代表的化合物:其盐,其溶剂化合物,或其前药。其中所有符号均如规范所定义。本发明的化合物具有对CXCR4的拮抗活性,因此可用作预防和/或治疗CXCR4介导的疾病的药物,例如,炎症和免疫性疾病(例如,类风湿性关节炎,关节炎,系统性红斑狼疮,视网膜病变,黄斑变性,肺纤维化,移植器官排斥等),过敏性疾病,感染(例如,人类免疫缺陷病毒感染,获得性免疫缺陷综合症等),精神神经疾病,脑部疾病,心血管疾病,代谢性疾病,癌症(例如,癌症,癌症转移等),或再生治疗药物。